ABAC Therapeutics (ABAC) develops new targeted antibiotics for patients with severe infections.
ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 15, 2018 | Series A | €16M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Global health sciences venture fund | — | Series A |